9.18
0.88%
+0.08
Handel nachbörslich:
9.18
Schlusskurs vom Vortag:
$9.10
Offen:
$9.08
24-Stunden-Volumen:
365.64K
Marktkapitalisierung:
$537.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-201.59M
KGV:
-2.0959
EPS:
-4.38
Netto-Cashflow:
$-139.21M
1W Leistung:
+2.34%
1M Leistung:
-12.57%
6M Leistung:
+7.75%
1J Leistung:
-10.09%
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
877 742 8466
Adresse
100 Campus Drive, Suite 102, Florham Park, NJ
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-03-13 | Eingeleitet | Craig Hallum | Buy |
2022-10-21 | Eingeleitet | Jefferies | Buy |
2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
2021-02-02 | Eingeleitet | Guggenheim | Buy |
2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
2019-11-19 | Eingeleitet | Goldman | Neutral |
2019-11-19 | Eingeleitet | Jefferies | Buy |
2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
GlobeNewswire Inc.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
GlobeNewswire Inc.
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Benzinga
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GlobeNewswire Inc.
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Phathom Pharmaceuticals Inc (PHAT) Nettogewinn 2024
PHAT betrug am 2023-12-31 der Nettogewinn der letzten 12 Monate -201.59 Millionen US-Dollar, was einem Rückgang von -1.96% im Vergleich zum Vorjahr entspricht.
Phathom Pharmaceuticals Inc (PHAT) Free Cashflow 2024
PHAT verzeichnete einen Free Cashflow der letzten 12 Monate von -139.21 Millionen US-Dollar für das Quartal bis zum 2023-12-31, was einem Anstieg von +5.66% im Vergleich zum Vorjahr entspricht.
Phathom Pharmaceuticals Inc (PHAT) Gewinn je Aktie 2024
Der Gewinn je Aktie (EPS) von PHAT für die letzten 12 Monate betrug -3.94 US-Dollar für das Quartal, das am 2023-12-31 endete, was einem Wachstum von +21.98% im Vergleich zum Vorjahr entspricht.
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Curran Terrie | President and Chief Executive |
Mar 22 '24 |
Sale |
9.11 |
16,851 |
153,513 |
410,784 |
TAKEDA PHARMACEUTICAL CO LTD | 10% Owner |
Jan 24 '24 |
Sale |
8.10 |
3,703,703 |
29,999,994 |
3,755,583 |
Henderson Molly | CFO and CBO |
Jan 19 '24 |
Sale |
7.75 |
6,307 |
48,900 |
98,698 |
Henderson Molly | CFO and CBO |
Nov 20 '23 |
Sale |
7.24 |
2,127 |
15,403 |
103,061 |
Parikh Asit | Director |
Nov 08 '23 |
Buy |
7.80 |
2,500 |
19,500 |
55,000 |
Parikh Asit | Director |
Nov 07 '23 |
Buy |
7.76 |
4,000 |
31,040 |
52,500 |
Parikh Asit | Director |
Nov 06 '23 |
Buy |
8.04 |
1,000 |
8,040 |
48,500 |
Henderson Molly | CFO and CBO |
Nov 01 '23 |
Sale |
8.88 |
12,492 |
110,871 |
105,188 |
Henderson Molly | CFO and CBO |
Jun 02 '23 |
Sale |
11.41 |
1,960 |
22,368 |
68,506 |
Henderson Molly | CFO and CBO |
May 22 '23 |
Sale |
12.87 |
2,110 |
27,165 |
70,466 |
Kapitalisierung:
|
Volumen (24h):